Realbotix Corp announced it expects to deliver 19 previously ordered robots and corresponding AI implementations during March, April, and May 2026, according to a statement from Onconetix Inc (NASDAQ: ONCO).

The delivery update was shared by Onconetix as it relates to its pending acquisition of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp. Realbotix stated it continues to develop its pipeline while scaling production capacity and increasing demand for its humanoids and AI technology.

Onconetix entered into a definitive share exchange agreement on February 12, 2026, to acquire 100% of the equity interests of Realbotix LLC in an all-stock transaction. The combined company is expected to trade on Nasdaq following the closing, which is anticipated to occur in the second half of 2026.

The transaction remains subject to Onconetix shareholder approval, regulatory approvals, and other closing conditions. Onconetix intends to file a Registration Statement on Form S-4 with the SEC to register the common stock to be issued in connection with the proposed transaction.

Onconetix is a commercial-stage biotechnology company focused on oncology solutions and owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments, with manufacturing operations in the United States.